Pulnovo Medical, a pioneer in breakthrough therapies for treating Pulmonary Hypertension and Heart Failure, today announced the successful completion of an oversubscribed $100 million strategic ...
Morning Overview on MSN
New catheter aims to improve arrhythmia treatment as clinical trials begin
For the roughly 6 million Americans living with atrial fibrillation, catheter ablation has become an increasingly common ...
Infections from antibiotic-resistant bacteria are difficult to treat and are responsible for over 2.8 million infections and ...
Highlights include pooled safety findings from Paratek's Phase 3 studies in community acquired pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI), as well as additional ...
Woman's World on MSN
Baxdrostat, a new BP drug, could be a game-changer for hypertension
With almost half of American adults living with high blood pressure, it makes sense that you'd want every possible tool in ...
Tectonic Therapeutic is reviving relaxin biology with TX45, targeting Group 2 Pulmonary Hypertension with HFpEF. Check out ...
GSK has completed its 950 million dollar acquisition of 35Pharma, adding HS235, a promising pulmonary hypertension therapy, ...
GSK completes acquisition of Canada-based, clinical-stage biopharma company, 35Pharma Inc: London, UK Thursday, April 16, 2026, 09:00 Hrs [IST] GSK plc announced the completion of ...
RAPIBLYK (R) is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored hospital setting. Its pharmacological profile allows for rapid onset and ...
Allrock Bio has dosed the first participants in a small clinical trial testing ROC-101 as an add-on treatment for pulmonary ...
Cautionary Language Concerning Forward-Looking Statements ...
(Alliance News) - GSK PLC on Wednesday said it has completed the acquisition of Canada-based clinical stage biopharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results